XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt Obligations - 2027 Term Loan - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2022
USD ($)
Jan. 31, 2022
USD ($)
item
Mar. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 14, 2022
USD ($)
Jul. 01, 2022
Jan. 05, 2022
USD ($)
tranche
Apr. 30, 2020
USD ($)
Feb. 29, 2016
USD ($)
Debt Instrument [Line Items]                  
Outstanding amount paid off       $ 81,750          
Outstanding amount payoff       109,000          
2027 Term Loans | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount             $ 300,000    
Number of tranches | tranche             4    
Net carrying value       245,246          
Stated interest rate   8.25%              
Quarterly payments | item   5              
Loan agreement covenants, minimum trailing twelve month net sales for current quarter   $ 200,000              
Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024   210,000              
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended June 30, 2024   230,000              
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended September 30, 2024   270,000              
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended December 31, 2024 and thereafter   $ 300,000              
Mandatory prepayment term   10 days              
Debt discounts and issuance costs   $ 6,800              
Remaining unamortized debt discount and debt offering costs       4,754          
2027 Term Loans | BioPharma Credit Investments V GP LLC | Three-month LIBOR                  
Debt Instrument [Line Items]                  
Spread on variable rate   1.00%              
2027 Term Loans | Additional facility amount | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount   $ 100,000              
Tranche A Loan, funded January 5, 2022 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount             $ 100,000    
Debt discounts and issuance costs   7,800              
Tranche B Loan, funded no later than April 1, 2022 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount $ 100,000   $ 100,000            
Debt discounts and issuance costs     2,300            
Convertible notes, Issuance Cost $ 1,000   $ 1,000            
Tranche C Loan, funded between April 1, 2022 and March 17, 2023 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount   50,000              
Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount         $ 50,000        
Convertible notes, Issuance Cost         $ 500        
Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC | Three-month LIBOR                  
Debt Instrument [Line Items]                  
Effective interest rate         11.73%        
1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes                  
Debt Instrument [Line Items]                  
Principal amount               $ 230,000  
Net carrying value       225,250          
Stated interest rate               1.50%  
Remaining unamortized debt discount and debt offering costs       $ 4,750          
Effective interest rate       2.10%          
1.5% Convertible Senior Subordinated Notes due 2026 | BioPharma Credit Investments V GP LLC | Scenario, Plan | Minimum                  
Debt Instrument [Line Items]                  
Principal amount   50,000              
8.2% Convertible Notes due 2022 | Convertible Notes                  
Debt Instrument [Line Items]                  
Principal amount   100,000             $ 100,000
Stated interest rate 8.20%   8.20%           8.20%
Outstanding amount payoff $ 111,100 111,100              
2025 Term Loan                  
Debt Instrument [Line Items]                  
Net carrying value       $ 0          
2025 Term Loan | Convertible Notes                  
Debt Instrument [Line Items]                  
Principal amount   75,000              
Outstanding amount paid off   $ 81,900              
Tranche A and B Loans | BioPharma Credit Investments V GP LLC | Three-month LIBOR                  
Debt Instrument [Line Items]                  
Effective interest rate           10.54%      
Tranches A, B and D | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Remaining unamortized debt discount and debt offering costs       $ 4,800          
Remaining term       4 years 3 months 18 days